Welcome to our dedicated page for Kindly Md news (Ticker: KDLY), a resource for investors and traders seeking the latest updates and insights on Kindly Md stock.
KindlyMD Inc. (KDLY) operates at the intersection of traditional healthcare and innovative pain management, offering integrated services that combine primary care, behavioral health, and alternative therapies. This news hub provides investors and industry observers with timely, organized updates on the company’s strategic initiatives and clinical advancements.
Access comprehensive coverage of KDLY’s operational milestones, including earnings reports, telemedicine expansions, regulatory filings, and partnership announcements. Our curated collection features press releases about opioid reduction strategies, medical cannabis education programs, and healthcare data innovations that define the company’s patient-first approach.
Key updates include developments in chronic pain management protocols, behavioral health integrations, and telehealth service enhancements. Track KDLY’s progress in securing insurance partnerships, rural care initiatives, and clinical outcome improvements through data analytics.
Bookmark this page for streamlined access to verified KindlyMD news. Check regularly for updates on operational expansions, treatment efficacy studies, and regulatory compliance achievements that shape the company’s position in value-based healthcare.
KindlyMD (NASDAQ: KDLY), a healthcare company integrating traditional primary care with pain management and alternative therapies, has announced its participation in two upcoming investor conferences in October 2024. CEO Tim Pickett will represent the company at both events:
1. Benzinga Cannabis Capital Conference (October 8-9, Chicago):
- Panel: The Medical Cannabis Experience: Best Practices For Patient Access, Care And Loyalty
- Date/Time: October 9th at 12:50 p.m. MT
2. LD Micro Main Event XVII (October 28-30, Los Angeles):
- Presentation: October 29th at 12:30 p.m. MT, Track 4
Webcasts for both events will be available on the KindlyMD investor relations website. Investors interested in one-on-one meetings with Mr. Pickett can contact Benzinga, LD Micro representatives, or email KCSA Strategic Communications.
KindlyMD (NASDAQ:KDLY), a patient-first healthcare and healthcare data company, has been recognized with the Healthcare AI Impact Award 2024. The award highlights companies driving improvements in patient care and operational efficiency through AI. KindlyMD was selected from over 400 submissions for its innovative work in leveraging patient data for diagnostics, particularly in exploring the effective use of cannabis in medical treatment.
The company is utilizing machine learning to trace patterns and create models that enhance their care model and improve patient outcomes. Tim Pickett, KindlyMD's founder and CEO, emphasized their commitment to pushing AI boundaries in healthcare to personalize alternative treatments to opioids and help patients make more informed therapeutic decisions.
KindlyMD (NASDAQ:KDLY) has appointed Dr. Jeremy Joyal as Medical Director. Dr. Joyal, a licensed physician with board certifications in Anesthesiology, Pain Medicine, and Addiction Medicine, will oversee the company's clinical practices and develop program protocols for pain management. His responsibilities include ensuring adherence to current standards, implementing advanced pain management programs, and collaborating with healthcare providers to ensure comprehensive patient care across KindlyMD's platform.
Dr. Joyal's expertise is expected to enhance KindlyMD's clinical operations and patient care. He graduated from Brigham Young University with a degree in Neuroscience and earned his MD from the Medical College of Wisconsin. Dr. Joyal specialized in Anesthesiology at Washington University in St. Louis and completed a Pain Medicine fellowship at the University of Utah in 2014.
KindlyMD (NASDAQ: KDLY), a healthcare company integrating traditional primary care with pain management and alternative therapies, announces CEO Tim Pickett's participation in H.C. Wainwright's 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024, at the Lotte New York Palace Hotel.
Key points:
- Pickett will present virtually and engage in one-on-one investor meetings
- The presentation will be available on-demand from 7:00 a.m. ET
- Investors can schedule meetings through H.C. Wainwright representatives or KCSA Strategic Communications
- A replay of the presentation will be accessible for at least 90 days on KindlyMD's investor website
This conference provides KindlyMD an opportunity to showcase its unique approach to healthcare and connect with potential investors.
KindlyMD (NASDAQ:KDLY) has appointed Nancy Pratt as Behavioral Health Program Director to enhance its Complete Care and Therapy services. Pratt, a clinical mental health counselor (CMHC) with over 10 years of experience, specializes in suicide assessment and treatment for anxiety, depression, and trauma. She holds a Master of Science in Clinical Mental Health Counseling from Westminster College and has a background in creating programs for at-risk youth.
CEO Tim Pickett emphasized that Pratt's expertise will be instrumental in designing and implementing the Complete Care program, which is central to KindlyMD's mission of delivering targeted, holistic healthcare. This appointment aligns with the company's strategy to integrate traditional primary care and pain management with behavioral and alternative therapies.
KindlyMD (NASDAQ:KDLY) announced its Q2 2024 financial results and provided a shareholder update. Key highlights include:
1. Nearly 80% statewide comprehensive insurance coverage in Utah under contract with providers like Medicare, Select Health, Medicaid, and Blue Cross Blue Shield.
2. 163.7% sequential increase in reimbursement from insurance payors, totaling $126,325 in H1 2024 compared to $0 in H1 2023.
3. Completed IPO in June 2024 for net proceeds of $6.02 million.
4. Q2 2024 revenues decreased by 34.8% to $639,057, primarily due to a shift towards insurance billing.
5. Operating expenses increased by 6.0% to $1,676,250 in Q2 2024.
6. Net loss per share increased to $(0.26) in Q2 2024 from $(0.13) in Q2 2023.
7. As of June 30, 2024, cash and cash equivalents stood at $4.74 million with total working capital of $4.11 million.
KindlyMD (NASDAQ:KDLY), a healthcare and data company integrating traditional primary care with pain management and alternative therapies, has announced its participation in two upcoming investor conferences in August 2024:
1. Sidoti Micro-Cap Virtual Conference: Presenting on Wednesday, August 14th at 11:30 a.m. ET
2. Summer 2024 Investor Summit Virtual Conference: Presenting on Tuesday, August 20th at 12:30 p.m. ET
Both presentations will be available via webcast. Investors can schedule one-on-one meetings with KindlyMD's management team through Sidoti, Investor Summit Group, or by contacting KCSA Strategic Communications.
KindlyMD (NASDAQ:KDLY) has submitted a comment to the U.S. Department of Justice regarding the proposed reclassification of cannabis from Schedule I to Schedule III of the Controlled Substances Act. The company welcomes this potential change, which aligns with the growing recognition of cannabis's medical benefits. Key points:
1. Reclassification does not legalize marijuana federally.
2. It may reduce patient costs for medical cannabis products.
3. Cannabis businesses could deduct more expenses, potentially adding significant amounts to their balance sheets.
4. The change creates a more favorable business environment for KindlyMD, possibly enabling service expansion and reduced operational risks.
5. KindlyMD's integrated healthcare model remains relevant, particularly in providing medical cannabis education and evaluation in Utah.
KindlyMD, a healthcare company integrating primary care and pain management, announced its Q1 2024 financial results after its IPO on June 3, 2024.
Key highlights include:
- Revenue of $829,029, a 28.6% decrease from Q1 2023, due to a shift to insurance billing.
- First-time insurance reimbursements of $34,722, compared to $0 in Q1 2023.
- Operating expenses decreased by 21.9% to $1,066,156.
- Net loss per share reduced by 50% to $(0.06).
Post-IPO, KindlyMD raised $6.02 million, ensuring sufficient funding for the next 12 months. Additionally, the company secured contracts with major insurers, providing nearly 80% statewide coverage in Utah and plans to expand through acquisitions and marketing investments.
KindlyMD (NASDAQ: KDLY) has successfully registered on SAM.gov, enabling it to apply for and secure federal funds and contracts. On April 27, 2024, the company submitted its first grant application for the USDA’s Rural Utilities Service Distance Learning and Telemedicine (DLT) Grant Program, aiming to secure $1,000,000 to expand its Complete Care telehealth program in rural Utah. This initiative combines primary care, pain management, and mental health services. Successfully registering on SAM.gov paves the way for KindlyMD to pursue further grants, including SBIRT, ROTA, and MAT-PDOA, to enhance their comprehensive healthcare solutions.
FAQ
What is the current stock price of Kindly Md (KDLY)?
What is the market cap of Kindly Md (KDLY)?
